Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 10;15(2):e0227928.
doi: 10.1371/journal.pone.0227928. eCollection 2020.

miRNA expression in advanced Algerian breast cancer tissues

Mohamad Ali Tfaily  1 , Farah Nassar  1 , Leila-Sarah Sellam  2 , Zine-Charaf Amir-Tidadini  3 , Fatima Asselah  3 , Mehdi Bourouba  2 , Nasr Rihab  1
Affiliations

miRNA expression in advanced Algerian breast cancer tissues

Mohamad Ali Tfaily et al. PLoS One. .

Abstract

Breast cancer is one of the commonest cancers among Algerian females. Compared to Western populations, the median age of diagnosis of breast cancer is much lower in Algeria. The objective of this study is to explore the expression of several miRNAs reported to be deregulated in breast cancer. The miRNAs miR-21, miR-125b, miR-100, miR-425-5p, miR-200c, miR-183 and miR-182 were studied on tumor and normal adjacent Algerian breast tissues using quantitative reverse transcription real time PCR, and the results were analyzed according to clinical characteristics. Compared to the normal adjacent tissues, miR-21, miR-183, miR-182, miR-425-5p and miR-200c were found to be upregulated while miR-100 and miR-125b were insignificantly deregulated. A positive correlation was noted among miR-183, miR-182 and miR-200c and among miR-425-5p, miR-183, miR-200c and miR-21. Further global miRNA microarray profiling studies can aid in finding ethnic specific miRNA biomarkers in the Algerian breast cancer population.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Upregulated miRNA expression in Algerian breast cancer tissues.
Dot plots show the fold change of expression of miR-183, miR-182, miR-200c, miR-425-5p and miR-21 in tumor breast cancer tissues compared to the normal adjacent tissues, obtained using RT-qPCR with RNU6B as an endogenous control. * signifies p<0.05, using Wilcoxon signed rank test.
Fig 2
Fig 2. Deregulated miRNA expression in Algerian breast cancer tissues.
Dot plots show the fold change of expression of miR-100 and miR-125b in tumor breast cancer tissues compared to the normal adjacent tissues, obtained using RT-qPCR with RNU6B as an endogenous control.
Fig 3
Fig 3. Heatmap and dendogram analysis of miRNA expression in normal and BC tissues.
Fold expression data were Log2 transformed before analysis. miRNA profiling segregated the tumor tissues and the normal adjacent tissues. Left-hand side dendrogram corresponds to a hierarchical clustering of the tissue samples. The upper side dendrogram corresponds to a hierarchical clustering of miRNA expression in the FFPE tissues. Grey boxes denote tumor samples and yellow boxes denote normal adjacent tissues.
Fig 4
Fig 4. Significant deregulation of miR-21 (A) and miR-125b (B) expression with HER2 status.
Dot plots represent the fold change of expression of miR-21 in HER2+, HER2- and normal adjacent tissues. *denotes p<0.05 for tumor versus normal using Wilcoxon signed rank test. #denotes p<0.05 using Mann-Whitney test.
Fig 5
Fig 5. Pathway studio network analysis of the studied microRNA in breast cancer.
A biological network was created using the Pathway Studio 9.0 program to visualize the role of different microRNA discussed in this manuscript in chosen breast cancer-related pathways.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Jacques F, Isabelle S, Rajesh D, Sultan E, Colin M, Marise R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2015;136(5):E359–E86. 10.1002/ijc.29210 - DOI - PubMed
    1. Globocan 2018: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2018 http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx:
    1. Uhrhammer N, Abdelouahab A, Lafarge L, Feillel V, Ben Dib A, Bignon YJ. BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases. Int J Med Sci. 2008;5(4):197–202. 10.7150/ijms.5.197 - DOI - PMC - PubMed
    1. Cherbal F, Bakour R, Adane S, Boualga K, Benais-Pont G, Maillet P. BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families. Dis Markers. 2010;28(6):377–84. 10.3233/DMA-2010-0718 - DOI - PMC - PubMed
    1. Najjar H, Easson A. Age at diagnosis of breast cancer in Arab nations. Int J Surg. 2010;8(6):448–52. 10.1016/j.ijsu.2010.05.012 - DOI - PubMed

Grants and funding

The authors received no specific funding for this work.
  NODES
INTERN 1
Note 4
twitter 2